FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative anemia and fibrosis therapies, the company’s reputation and market value declined sharply after 2020 following a series of late-stage trial failures, regulatory setbacks, and a data manipulation scandal involving its former chief medical officer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| FGEN | FIBROGEN INC | 2025-10-28 15:10:04 | 10.81 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FGEN | 0000921299 | FIBROGEN INC | US31572Q8814 | 549300Q914ULWWY95822 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 350 BAY STREET | SAN FRANCISCO | CA | 94133 | UNITED STATES | US | 415-978-1200 | 350 BAY STREET, SAN FRANCISCO, CA, 94133 | 350 BAY STREET, SAN FRANCISCO, CA, 94133 | — | Biotechnology | 1993 | Thane Wettig | 52 | http://fibrogen.com | 88,400,000 | 4,044,000 | 4,043,899 | FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative anemia and fibrosis therapies, the company’s reputation and market value declined sharply after 2020 following a series of late-stage trial failures, regulatory setbacks, and a data manipulation scandal involving its former chief medical officer. | 2025-10-23 16:33:55 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 88,400,000 | -173,100,000 | -66.195 | 100,916,956 | 2,145,709 | 2.1724 |
| 2023 | 261,500,000 | -713,600,000 | -73.1822 | 98,771,247 | 4,588,332 | 4.8717 |
| 2022 | 975,100,000 | -471,700,000 | -32.603 | 94,182,915 | 1,180,947 | 1.2698 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 52 |
| 2023 | 486 |
| 2022 | 592 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 29,621,000 | 147,752,000 | 140,734,000 |
| Cost Of Revenue | 15,561,000 | 18,848,000 | 20,280,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 95,692,000 | 282,861,000 | 296,791,000 |
| General And Administrative Expenses | 49,330,000 | 115,252,000 | 124,688,000 |
| Operating Expenses | 180,037,000 | 429,567,000 | 441,759,000 |
| Operating Income | -150,416,000 | -281,815,000 | -301,025,000 |
| Net Income | -47,579,000 | -284,232,000 | -293,654,000 |
| Earnings Per Share Basic | -0.48 | -2.92 | -3.14 |
| Earnings Per Share Diluted | -0.48 | -2.92 | -3.14 |
| Weighted Average Shares Outstanding Basic | 100,044,000 | 97,303,000 | 93,582,000 |
| Weighted Average Shares Outstanding Diluted | 100,044,000 | 97,303,000 | 93,582,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 50,482,000 | 113,688,000 | 155,700,000 |
| Marketable Securities Current | 0 | 121,898,000 | 266,308,000 |
| Accounts Receivable | 481,000 | 12,553,000 | 16,299,000 |
| Inventories | 3,155,000 | 41,565,000 | 40,436,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,139,000 | 6,711,000 | 4,353,000 |
| Total Assets Current | 196,509,000 | 331,559,000 | 492,826,000 |
| Marketable Securities Non Current | 0 | — | — |
| Property Plant And Equipment | 0 | 13,126,000 | 20,605,000 |
| Other Assets Non Current | 1,405,000 | 3,803,000 | 5,282,000 |
| Total Assets Non Current | 18,016,000 | 91,970,000 | 117,261,000 |
| Total Assets | 214,525,000 | 423,529,000 | 610,087,000 |
| Accounts Payable | 5,064,000 | 17,960,000 | 30,758,000 |
| Deferred Revenue | 27,290,000 | 12,740,000 | 12,739,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 62,035,000 | 172,891,000 | 219,773,000 |
| Total Liabilities Current | 133,306,000 | 217,668,000 | 273,562,000 |
| Long Term Debt | 73,092,000 | 71,934,000 | — |
| Other Liabilities Non Current | 822,000 | 2,858,000 | 6,440,000 |
| Total Liabilities Non Current | 264,854,000 | 368,060,000 | 338,005,000 |
| Total Liabilities | 398,160,000 | 585,728,000 | 611,567,000 |
| Common Stock | 1,009,000 | 988,000 | 942,000 |
| Retained Earnings | -1,889,499,000 | -1,841,920,000 | -1,557,688,000 |
| Accumulated Other Comprehensive Income | -5,732,000 | -6,875,000 | -5,720,000 |
| Total Shareholders Equity | -225,602,000 | -204,166,000 | -21,447,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,654,000 | 9,518,000 | 10,017,000 |
| Share Based Compensation Expense | 25,215,000 | 50,767,000 | 65,601,000 |
| Other Non Cash Income Expense | — | 1,000,000 | — |
| Change In Accounts Receivable | 6,737,000 | -3,433,000 | -765,000 |
| Change In Inventories | -22,284,000 | 1,695,000 | 10,999,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -1,010,000 | -256,000 | -263,000 |
| Change In Accounts Payable | 14,512,000 | -15,514,000 | 5,909,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -137,999,000 | -315,021,000 | -145,933,000 |
| Purchases Of Marketable Securities | 8,628,000 | 251,830,000 | 164,023,000 |
| Sales Of Marketable Securities | 133,841,000 | 400,621,000 | 284,492,000 |
| Acquisition Of Property Plant And Equipment | 266,000 | 2,519,000 | 3,741,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 125,993,000 | 153,657,000 | 89,116,000 |
| Tax Withholding For Share Based Compensation | 354,000 | 237,000 | 5,167,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 139,000 | 3,731,000 | 4,184,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -255,000 | 122,749,000 | 46,776,000 |
| Change In Cash | -11,510,000 | -42,012,000 | -15,523,000 |
| Cash At End Of Period | 50,482,000 | 113,688,000 | 155,700,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 16,207,000 | 54,000 | 104,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.48 | -2.92 | -3.14 |
| Price To Earnings Ratio | -27.5781 | -7.5882 | -127.5478 |
| Earnings Growth Rate | -83.5616 | -7.0064 | — |
| Price Earnings To Growth Ratio | 0.33 | 1.083 | — |
| Book Value Per Share | -1.8355 | -1.6669 | -0.0158 |
| Price To Book Ratio | -7.2118 | -13.2923 | -25,324.048 |
| Ebitda | -36,678,000 | -259,182,000 | -282,197,000 |
| Enterprise Value | 1,346,942,450 | 2,114,237,222.5 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.324 | -0.3523 | — |
| Capital Expenditures | -10,472,000 | 2,039,000 | 2,345,000 |
| Free Cash Flow | -127,527,000 | -317,060,000 | -148,278,000 |
| Return On Equity | 0.2109 | 1.3922 | 13.6921 |
| One Year Beta | 1.4838 | 2.2482 | 1.2486 |
| Three Year Beta | 1.4597 | 1.4299 | 1.2622 |
| Five Year Beta | 1.3523 | 1.368 | 1.3221 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Wettig Thane | Director, CEO | 2025-09-06 | 248 | D | 21,239 |
| DeLucia David | Chief Financial Officer | 2025-09-06 | 53 | D | 4,541 |
| Schoeneck James A | Director | 2025-06-30 | 23,567 | A | 39,666 |
| Wettig Thane | Director, CEO | 2025-06-06 | 246 | D | 21,487 |
| DeLucia David | Chief Financial Officer | 2025-06-06 | 51 | D | 4,594 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| OSAIC HOLDINGS, INC. | 2025-06-30 | 3,402 | 642 | 5.2991 |
| WOLVERINE TRADING, LLC | 2025-06-30 | 55,332 | 10,600 | 5.22 |
| NATIONAL BANK OF CANADA /FI/ | 2025-06-30 | 1,009 | 193 | 5.228 |
| MORGAN STANLEY | 2025-06-30 | 8,799 | 1,660 | 5.3006 |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 4,203 | 793 | 5.3001 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 5,744 | 67,951.52 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 7,047 | 83,366.01 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 1,991 | 23,553.53 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 21,987 | 260,106.21 | 0.0006 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 16 | 116.53 | 0.0 |